” Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 percent to $697 million as competition from generic drug companies reduced sales. Revenue declined 6.7 percent to $6.31 billion as stomach-acid treatment Nexium lost patent exclusivity in the U.S. and cholesterol treatment Crestor faced competition from generic drugs.

Click here to read original article